Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Microb Pathog ; 189: 106596, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38395317

RESUMO

Botulism is a severe disease caused by potent botulinum neurotoxins (BoNTs) produced by Clostridium botulinum. This disease is associated with high-lethality outbreaks in cattle, which have been linked to the ingestion of preformed BoNT serotypes C and D, emphasizing the need for effective vaccines. The potency of current commercial toxoids (formaldehyde-inactivated BoNTs) is assured through tests in guinea pigs according to government regulatory guidelines, but their short-term immunity raises concerns. Recombinant vaccines containing the receptor-binding domain have demonstrated potential for eliciting robust protective immunity. Previous studies have demonstrated the safety and effectiveness of recombinant E. coli bacterin, eliciting high titers of neutralizing antibodies against C. botulinum and C. perfringens in target animal species. In this study, neutralizing antibody titers in cattle and the long-term immune response against BoNT/C and D were used to assess the efficacy of the oil-based adjuvant compared with that of the aluminum hydroxide adjuvant in cattle. The vaccine formulation containing Montanide™ ISA 50 yielded significantly higher titers of neutralizing antibody against BoNT/C and D (8.64 IU/mL and 9.6 IU/mL, respectively) and induced an immune response that lasted longer than the response induced by aluminum, extending between 30 and 60 days. This approach represents a straightforward, cost-effective strategy for recombinant E. coli bacterin, enhancing both the magnitude and duration of the immune response to botulism.


Assuntos
Toxinas Botulínicas , Botulismo , Clostridium botulinum , Bovinos , Animais , Cobaias , Botulismo/prevenção & controle , Botulismo/veterinária , Hidróxido de Alumínio , Escherichia coli/genética , Vacinas Bacterianas/genética , Toxinas Botulínicas/genética , Clostridium botulinum/genética , Adjuvantes Imunológicos , Anticorpos Neutralizantes , Imunidade , Anticorpos Antibacterianos
2.
Pesqui. vet. bras ; 40(10): 776-780, Oct. 2020. tab, graf
Artigo em Inglês | VETINDEX, LILACS | ID: biblio-1143413

RESUMO

Clostridium perfringens is considered one of the main causative agents of superacute enterocolitis, usually fatal in the equine species, due to the action of the ß toxin, and is responsible for causing severe myonecrosis, by the action of the α toxin. The great importance of this agent in the equine economy is due to high mortality and lack of vaccines, which are the main form of prevention, which guarantee the immunization of this animal species. The aim of this study was to evaluate three different concentrations (100, 200 and 400µg) of C. perfringens α and ß recombinant toxoids in equine immunization and to compare with a group vaccinated with a commercial toxoid. The commercial vaccine was not able to stimulate an immune response and the recombinant vaccine was able to induce satisfactory humoral immune response in vaccinated horses, proving to be an alternative prophylactic for C. perfringens infection.(AU)


Clostridium perfringens é considerado um dos principais agentes causadores de enterocolites superagudas, geralmente fatais na espécie equina, devido à ação da toxina ß, além de ser responsável por causar quadros graves de mionecrose, pela ação da toxina α. A grande importância desses agentes na equinocultura, deve-se a elevada mortalidade e a inexistência de vacinas, principal forma de prevenção, que garantam a imunização dessa espécie animal. O objetivo deste trabalho foi avaliar três diferentes concentrações (100, 200 e 400µg) dos toxóides recombinantes α e ß de C. perfringens na imunização de equinos, bem como comparar com um grupo vacinado com um toxóide comercial. A vacina comercial não se mostrou capaz de estimular uma resposta imune e a vacina recombinante foi capaz de induzir resposta imune humoral satisfatória em equinos vacinados, provando ser uma alternativa profilática para infecção por C. Perfringens.(AU)


Assuntos
Animais , Toxoides , Enterocolite Pseudomembranosa/veterinária , Vacinas Sintéticas/uso terapêutico , Clostridium perfringens/imunologia , Gangrena Gasosa/veterinária , Cavalos , Imunização/veterinária
3.
Biotechnol Lett ; 42(11): 2223-2230, 2020 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-32500473

RESUMO

OBJECTIVES: Earlier studies have demonstrated the use of inactivated recombinant E. coli (bacterins), to protect against Clostridium spp. in vaccinated animals. These bacterins have a simpler, safer, and faster production process. However, these bacterins carry expression plasmids, containing antibiotic resistance gene, which could be assimilate accidentally by environmental microorganisms. Considering this, we aimed to impair this plasmids using formaldehyde at different concentrations. RESULTS: This compound inactivated the highest density of cells in 24 h. KanR cassette amplification was found to be impaired with 0.8% for 24 h or 0.4% for 72 h. Upon electroporation, E. coli DH5α ultracompetent cells were unable to acquire the plasmids extracted from the bacterins after inactivation procedure. Formaldehyde-treated bacterins were incubated with other viable strains of E. coli, leading to no detectable gene transfer. CONCLUSIONS: We found that this compound is effective as an inactivation agent. Here we demonstrate the biosafety involving antibiotic resistance gene of recombinant E. coli vaccines allowing to industrial production and animal application.


Assuntos
Escherichia coli/genética , Formaldeído/farmacologia , Resistência a Canamicina/efeitos dos fármacos , Plasmídeos/efeitos dos fármacos , Escherichia coli/efeitos dos fármacos , Vacinas contra Escherichia coli/efeitos adversos , Vacinas contra Escherichia coli/genética , Transferência Genética Horizontal/efeitos dos fármacos , Plasmídeos/genética , Vacinas de Produtos Inativados , Vacinas Sintéticas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA